Sudeh Izadmehr

Featured in: Favicon

nature.com Favicon

frontiersin.org Favicon

aacrjournals.org Favicon

biorxiv.org Favicon

cancerres.aacrjournals.org

Articles

Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial - Nature Medicine

Jan 19, 2024 | nature.com | Matthew D. Galsky |Sudeh Izadmehr |Edgar Gonzalez-Kozlova |Kevin Chan |Christos E. Kyriakopoulos |Mahalya Gogerly-Moragoda | +5 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02568-1, published online 2 October 2023. In the version of the article initially published, Diane M.
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial - Nature Medicine

Oct 2, 2023 | nature.com | Matthew D. Galsky |Sudeh Izadmehr |Edgar Gonzalez-Kozlova |Kevin Chan |Christos E. Kyriakopoulos |Robert M. Samstein | +5 more

AbstractCystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-altering. We initiated a phase 2 study in which patients with MIBC received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients achieving a clinical complete response (cCR) could proceed without cystectomy.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →